ベンラファキシンの世界市場レポート 2025年

ベンラファキシンの市場規模は、今後数年間で安定した成長が見込まれます。2029年の年間平均成長率（CAGR）は4.8％で、42億2,000万米ドルに成長します。予測期間中の成長は、慢性ストレスに対する懸念の高まり、パニック発作の頻度の増加、薬物抵抗性疾患に対する理解の深まり、神経生物学的要因に対する認識の高まり、個別化医療の重視の強化といった要因に起因すると考えられます。この期間の主な動向としては、デジタルヘルスとモニタリングの台頭、AIを活用した創薬、ドラッグデリバリーシステムの進歩、規制・政策の改善、治療モニタリングにおけるAIの活用などが挙げられます。

メンタルヘルス障害の有病率の増加は、ベンラファキシン市場の拡大を大きく促進すると予想されます。個人の思考、感情、行動、気分に影響を及ぼすメンタルヘルス障害は、苦痛をもたらし、日常機能を妨げる可能性があります。メンタルヘルス障害の増加は、非現実的な比較につながる過剰なソーシャルメディアの使用、ネットいじめ、対面での交流の減少などの要因によるところが大きく、これらすべてが不安やうつ病の発生率を高める原因となっています。ベンラファキシンは、脳内のセロトニンとノルエピネフリンのレベルを上昇させ、気分を調整し、うつ病、不安障害、パニック障害の症状を緩和する二重の作用機序により、これらの障害の管理に効果的です。例えば、2022年に米国国立精神衛生研究所（NIMH）は、米国の成人5,930万人（成人人口の23.1％）が精神疾患を経験し、男性（19.7％）に比べて女性の有病率が高い（26.4％）と報告しました。メンタルヘルスに対する意識が高まり続ける中、ベンラファキシンのような治療に対する需要が高まり、市場拡大に拍車がかかると予想されます。

個別化医療に対する需要の高まりは、ベンラファキシン市場の成長を加速させる構えです。個別化医療は、ヘルスケア治療を個人の遺伝的体質、ライフスタイル、特定の疾患特性に合わせて調整し、より効果的な結果をもたらします。このアプローチは、遺伝子調査の進歩により、ヘルスケアプロバイダーが、ベンラファキシンのような薬の代謝に影響を与える可能性のある特定の遺伝子変異を特定できるようになったため、普及しつつあります。遺伝子検査を利用することで、医師はベンラファキシンの投与量を調整したり、それぞれの患者にとってより効果的で安全な代替治療を選択したりすることができます。例えば、2024年2月、個別化医療連合（Personalized Medicine Coalition）は、米国食品医薬品局（FDA）が2023年に希少疾患に対する新たな個別化治療を16件承認し、2022年の6件から大幅に増加したと報告しました。このような個別化ヘルスケアへの注目の高まりは、より多くの患者が特定の遺伝子プロファイルに合わせた治療を求めるようになり、ベンラファキシンの需要を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ベンラファキシンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のベンラファキシン市場：成長率分析
• 世界のベンラファキシン市場の実績：規模と成長, 2019-2024
• 世界のベンラファキシン市場の予測：規模と成長, 2024-2029, 2034F
• 世界ベンラファキシン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のベンラファキシン市場処方別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 徐放性カプセル
• 即放錠
• 経口溶液
• 世界のベンラファキシン市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗うつ薬
• 選択的セロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）
• 世界のベンラファキシン市場人口統計別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人用
• 小児科
• 高齢者
• 世界のベンラファキシン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• パニック障害
• うつ
• 不安
• 社会不安障害
• その他のアプリケーション
• 世界のベンラファキシン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他のエンドユーザー
• 世界のベンラファキシン市場徐放性カプセルの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 37.5mgカプセル
• 75mgカプセル
• 150mgカプセル
• 225mgカプセル
• 世界のベンラファキシン市場即放錠の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 25mg錠
• 37.5mg錠
• 50mg錠
• 75mg錠
• 100mg錠
• 世界のベンラファキシン市場経口液のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 25 mg/mL経口液
• 37.5 mg/mL経口液
• 50 mg/mL経口液

第7章 地域別・国別分析

• 世界のベンラファキシン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のベンラファキシン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ベンラファキシン市場：競合情勢
• ベンラファキシン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Takeda Pharmaceutical Company Limited.
• Viatris Inc.
• Teva Pharmaceutical Industries
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Dr Reddy's Laboratories.
• Zydus Cadila
• Lupin Pharmaceuticals
• Torrent Pharmaceuticals
• Taylor & Francis
• Stada Arzneimittel
• Taj Pharma
• Mesha Pharma
• Suzhou Pharmaceutical

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ベンラファキシン市場2029：新たな機会を提供する国
• ベンラファキシン市場2029：新たな機会を提供するセグメント
• ベンラファキシン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Venlafaxine is a prescription antidepressant that belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class. It is commonly prescribed for conditions such as major depressive disorder, anxiety disorders, and panic disorder. Venlafaxine works by increasing the levels of serotonin and norepinephrine in the brain and is available in both immediate and extended-release formulations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary formulations of venlafaxine include extended-release capsules, immediate-release tablets, and oral solutions. The extended-release capsules are designed to gradually release the medication over time, providing a consistent effect throughout the day. Venlafaxine is classified under various drug categories, including antidepressants and selective serotonin and norepinephrine reuptake inhibitors (SNRIs), and is used across different age groups, such as adults, children, and older adults. It is prescribed for multiple conditions, including panic disorder, depression, anxiety, and social anxiety disorder, and is used in various healthcare settings, such as clinics and hospitals.

The venlafaxine market research report is one of a series of new reports from The Business Research Company that provides venlafaxine market statistics, including venlafaxine industry global market size, regional shares, competitors with a venlafaxine market share, detailed venlafaxine market segments, market trends and opportunities, and any further data you may need to thrive in the venlafaxine industry. This venlafaxine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The venlafaxine market size has grown strongly in recent years. It will grow from$3.33 billion in 2024 to $3.50 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth during the historical period can be attributed to factors such as the increasing severity of depression, a rise in anxiety symptoms, growing treatment resistance, a higher need for dose adjustments, an aging patient population, and various health-related factors.

The venlafaxine market size is expected to see steady growth in the next few years. It will grow to$4.22 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth during the forecast period can be attributed to factors such as increasing concerns about chronic stress, a higher frequency of panic attacks, greater understanding of medication-resistant conditions, growing awareness of neurobiological factors, and a stronger emphasis on personalized medicine. Key trends during this period include the rise of digital health and monitoring, AI-driven drug discovery, advancements in drug delivery systems, regulatory and policy improvements, and the use of AI in treatment monitoring.

The growing prevalence of mental health disorders is expected to significantly drive the expansion of the venlafaxine market. Mental health disorders, which affect an individual's thoughts, feelings, behavior, and mood, can result in distress and hinder daily functioning. The rise in mental health disorders is largely attributed to factors such as excessive social media use, leading to unrealistic comparisons, cyberbullying, and reduced face-to-face interactions, all of which contribute to higher rates of anxiety and depression. Venlafaxine is effective in managing these disorders through its dual mechanism of action, which increases the levels of serotonin and norepinephrine in the brain, helping to regulate mood and alleviate symptoms of depression, anxiety, and panic disorders. For instance, in 2022, the National Institute of Mental Health (NIMH) reported that 59.3 million adults in the U.S. (23.1% of the adult population) experienced mental illness, with females exhibiting a higher prevalence (26.4%) compared to males (19.7%). As mental health awareness continues to rise, the demand for treatments such as venlafaxine is expected to grow, fueling market expansion.

The increasing demand for personalized medicine is poised to accelerate the growth of the venlafaxine market. Personalized medicine tailors healthcare treatments to an individual's genetic makeup, lifestyle, and specific disease characteristics, resulting in more effective outcomes. This approach is becoming more prevalent due to advancements in genetic research, which allow healthcare providers to identify specific genetic variations that may affect how a person metabolizes medications such as venlafaxine. By using genetic testing, doctors can adjust the dosage of venlafaxine or choose alternative treatments that are more effective and safer for each patient. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. This growing focus on personalized healthcare is expected to drive the demand for venlafaxine, as more patients seek treatments that are tailored to their specific genetic profiles.

Regulatory approvals play a crucial role in the expansion of the venlafaxine market, enhancing product offerings and strengthening the competitive position of companies in the industry. Regulatory approvals from health authorities such as the U.S. Food and Drug Administration (FDA) are essential for ensuring the safety, efficacy, and quality of pharmaceutical products. For example, in August 2022, Zydus Lifesciences, an India-based pharmaceutical company, received FDA approval to market generic versions of venlafaxine extended-release tablets. These generic formulations, which are indicated for treating depression and anxiety, are available in various strengths, including 37.5 mg, 75 mg, 150 mg, and 225 mg. As more regulatory approvals are granted, the availability and accessibility of venlafaxine will increase, further driving market growth and expanding competition in the venlafaxine market.

Major players in the venlafaxine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, Takeda Pharmaceutical Company Limited., Viatris Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr Reddy's Laboratories., Zydus Cadila, Lupin Pharmaceuticals, Torrent Pharmaceuticals, Taylor & Francis, Stada Arzneimittel, Taj Pharma, Mesha Pharma, and Suzhou Pharmaceutical.

North America was the largest region in the venlafaxine market in 2024. The regions covered in venlafaxine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the venlafaxine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The venlafaxine market consists of sales of effexor xr, venlafaxine hydrochloride, venlafaxine extended-release tablets, effexor XR, and venlafaxine oral solution. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Venlafaxine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on venlafaxine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for venlafaxine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The venlafaxine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Formulation: Extended-Release Capsules; Immediate-Release Tablets; Oral Solution
• 2) By Drug Class: Antidepressant; Selective Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs)
• 3) By Demographic: Adult; Pediatric; Geriatric
• 4) By Application: Panic Disorder; Depression; Anxiety; Social Anxiety Disorder; Other Application
• 5) By End-User: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Extended-Release Capsules: 37.5 Mg Capsules; 75 Mg Capsules; 150 Mg Capsules; 225 Mg Capsules
• 2) By Immediate-Release Tablets: 25 Mg Tablets; 37.5 Mg Tablets; 50 Mg Tablets; 75 Mg Tablets; 100 Mg Tablets
• 3) By Oral Solution: 25 Mg/Ml Oral Solution; 37.5 Mg/Ml Oral Solution; 50 Mg/Ml Oral Solution
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; Thermo Fisher Scientific Inc.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Venlafaxine Market Characteristics

3. Venlafaxine Market Trends And Strategies

4. Venlafaxine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Venlafaxine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Venlafaxine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Venlafaxine Market Growth Rate Analysis
• 5.4. Global Venlafaxine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Venlafaxine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Venlafaxine Total Addressable Market (TAM)

6. Venlafaxine Market Segmentation

• 6.1. Global Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Extended-Release Capsules
• Immediate-Release Tablets
• Oral Solution
• 6.2. Global Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressant
• Selective Serotonin And Norepinephrine Reuptake Inhibitors (SNRIs)
• 6.3. Global Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatric
• 6.4. Global Venlafaxine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Panic Disorder
• Depression
• Anxiety
• Social Anxiety Disorder
• Other Application
• 6.5. Global Venlafaxine Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End-Users
• 6.6. Global Venlafaxine Market, Sub-Segmentation Of Extended-Release Capsules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 37.5 mg Capsules
• 75 mg Capsules
• 150 mg Capsules
• 225 mg Capsules
• 6.7. Global Venlafaxine Market, Sub-Segmentation Of Immediate-Release Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25 mg Tablets
• 37.5 mg Tablets
• 50 mg Tablets
• 75 mg Tablets
• 100 mg Tablets
• 6.8. Global Venlafaxine Market, Sub-Segmentation Of Oral Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25 mg/mL Oral Solution
• 37.5 mg/mL Oral Solution
• 50 mg/mL Oral Solution

7. Venlafaxine Market Regional And Country Analysis

• 7.1. Global Venlafaxine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Venlafaxine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Venlafaxine Market

• 8.1. Asia-Pacific Venlafaxine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Venlafaxine Market

• 9.1. China Venlafaxine Market Overview
• 9.2. China Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Venlafaxine Market

• 10.1. India Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Venlafaxine Market

• 11.1. Japan Venlafaxine Market Overview
• 11.2. Japan Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Venlafaxine Market

• 12.1. Australia Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Venlafaxine Market

• 13.1. Indonesia Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Venlafaxine Market

• 14.1. South Korea Venlafaxine Market Overview
• 14.2. South Korea Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Venlafaxine Market

• 15.1. Western Europe Venlafaxine Market Overview
• 15.2. Western Europe Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Venlafaxine Market

• 16.1. UK Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Venlafaxine Market

• 17.1. Germany Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Venlafaxine Market

• 18.1. France Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Venlafaxine Market

• 19.1. Italy Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Venlafaxine Market

• 20.1. Spain Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Venlafaxine Market

• 21.1. Eastern Europe Venlafaxine Market Overview
• 21.2. Eastern Europe Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Venlafaxine Market

• 22.1. Russia Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Venlafaxine Market

• 23.1. North America Venlafaxine Market Overview
• 23.2. North America Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Venlafaxine Market

• 24.1. USA Venlafaxine Market Overview
• 24.2. USA Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Venlafaxine Market

• 25.1. Canada Venlafaxine Market Overview
• 25.2. Canada Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Venlafaxine Market

• 26.1. South America Venlafaxine Market Overview
• 26.2. South America Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Venlafaxine Market

• 27.1. Brazil Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Venlafaxine Market

• 28.1. Middle East Venlafaxine Market Overview
• 28.2. Middle East Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Venlafaxine Market

• 29.1. Africa Venlafaxine Market Overview
• 29.2. Africa Venlafaxine Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Venlafaxine Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Venlafaxine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Venlafaxine Market Competitive Landscape And Company Profiles

• 30.1. Venlafaxine Market Competitive Landscape
• 30.2. Venlafaxine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Venlafaxine Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited.
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceutical Industries
• 31.5. Sun Pharmaceutical Industries Ltd.
• 31.6. Aurobindo Pharma
• 31.7. Dr Reddy's Laboratories.
• 31.8. Zydus Cadila
• 31.9. Lupin Pharmaceuticals
• 31.10. Torrent Pharmaceuticals
• 31.11. Taylor & Francis
• 31.12. Stada Arzneimittel
• 31.13. Taj Pharma
• 31.14. Mesha Pharma
• 31.15. Suzhou Pharmaceutical

32. Global Venlafaxine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Venlafaxine Market

34. Recent Developments In The Venlafaxine Market

35. Venlafaxine Market High Potential Countries, Segments and Strategies

• 35.1 Venlafaxine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Venlafaxine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Venlafaxine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r35017_Venlafaxine_GMR_2025